Stay updated on Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now indicates that the study is no longer recruiting participants, signaling that enrollment has closed. It also introduces new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Interventions/Treatment header formatting, plus a revision tag update to v3.6.0.SummaryDifference0.6%

- Check18 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing Revision: v3.5.4. This is an administrative update and does not alter the study information shown to users.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing v3.5.3. This indicates a routine platform update that updates internal versioning rather than study information.SummaryDifference0.1%

- Check46 days agoChange DetectedThe study's Indiana-based affiliation was updated from Indiana University School of Medicine to Indiana University, changing the credited institution in the collaborators/locations section. This reflects a broader institutional naming for the site and may affect how the record is identified in communications and databases.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page’s revision/build indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check68 days agoChange DetectedFooter revision label updated from Revision: v3.5.0 to Revision: v3.5.2. This indicates a minor site maintenance update with no changes to study content or data visible on the page.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.